Mitokinin
Dr. Wang is a Principal Scientist at Mitokinin. In that role, he is tasked with investigating the impact of PINK1 amplification on Parkinson’s disease pathobiology across numerous model systems, including human patient-derived iPSC neurons.
Dr. Wang brings over a decade of experience working in leading neuroscience labs to Mitokinin. He completed his Ph.D at the Institute for Neuroscience at the Chinese Academy of Sciences in Shanghai. He then completed his Postdoctoral training in the lab of Yadong Huang at the Gladstone Institutes UCSF), where he investigated apoE4 and tau in hiPSC models of Alzheimer’s disease. His work has been published in leading journals, including Nature Medicine, Cell Stem Cell, and Nature Cell Biology.
This person is not in any offices
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.